

MAR 01 2005

PTO/SB/97 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to
1-703-872-9306 at the United States Patent and Trademark Office

on March 1, 2005
Date


Signature

RAQUEL GARCIA

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Petition For Extension Of Time (in duplicate)
Response Under 37 CFR 1.116

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No. BM45323

MAR 01 2005

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ruelle, Jean-Louis

Group Art Unit: 1645

Serial No.: 09/701,271

Examiner: Baskar, Padmavathi

Filed: March 11, 2002

For: Neisseria Meningitidis Antigenic Polypeptides, Corresponding Polynucleotides and Protective Antibodies

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BEST AVAILABLE COPY

RESPONSE UNDER 37 CFR § 1.116

This paper is responsive to the Final Office Action mailed September 2, 2004. Applicant respectfully requests entry of this Amendment and reconsideration of the application in view thereof. It is believed that this Amendment is timely filed on or before March 2, 2005, with a three month extension of time.

Remarks

Claims 31, 39, 60-62, and 65 stand rejected; and claims 36-37, 68-69, and 71 have previously been cancelled without prejudice. Claim 38 is allowed. Claims 31, 38-39, 60-62, and 65 are currently pending. Applicant would like to thank the Examiner of the indication of allowable subject matter, reconsideration of the sole remaining rejection is respectfully requested.

Claim Rejections - 35 U.S.C. §102(b), Martin et al.

Claims 31, 39, 60-62, 65, and 71 stand rejected under 35 U.S.C. §102(b) for allegedly being anticipated by Martin et al. In particular, the Office Action asserts that Martin et al. discloses outer membrane protein from whole cell lysate preparations from N. meningitidis. The Office Action notes that monoclonal antibodies were produced by immunizing mice with the